Myth: No FDA Warning Letter Means a Stem Cell Clinic Is Safe and Legitimate

It's an understandable assumption: if a clinic were really doing something wrong, wouldn't the FDA have already shut it down? In reality, the absence of a public FDA enforcement action says very little about whether a stem cell clinic's treatment is safe, proven, or legitimate. This article explains what a warning letter actually is, why the FDA's enforcement reach is far smaller than the industry it's meant to oversee, and what more meaningful signals patients can actually check.

The Myth

Many patients reasonably treat "the FDA hasn't taken action against this clinic" as implicit proof of legitimacy — essentially assuming regulatory silence equals regulatory approval. It's an intuitive leap, but it isn't how FDA oversight of this industry actually works in practice.

What an FDA Warning Letter Actually Is

A warning letter is a notice the FDA issues after identifying what it believes is a significant violation — it is a tool for flagging problems the agency has already found and investigated, not a comprehensive certification system that continuously screens every clinic in the country before problems occur. The FDA has limited enforcement resources relative to the scale of the industry it oversees, and a warning letter typically arrives only after a clinic has already come to the agency's attention, often following a complaint, inspection, or reported adverse event — which means plenty of clinics operating in violation of federal rules simply haven't been formally flagged yet, not because they're compliant, but because enforcement hasn't reached them.

The Scale of the Gap

The scope of this gap has been documented by independent researchers tracking the industry over time. A widely cited 2016 study published in Cell Stem Cell by stem cell researcher Paul Knoepfler and bioethicist Leigh Turner identified 570 clinic locations, operated by 351 U.S. businesses, that were marketing purportedly stem cell-based interventions directly to consumers without apparent FDA approval. A follow-up analysis by Turner found that by March 2021, that number had grown substantially — to roughly 2,754 clinics operated by about 1,480 businesses — a more than fourfold increase in clinic locations over five years. Against that scale, the number of FDA warning letters issued to stem cell clinics each year is a small fraction of the total number of businesses identified as potentially marketing unapproved products. The math alone makes clear that an absence of a warning letter cannot be read as a clean bill of health; it's at least as likely to simply mean a clinic hasn't yet been reviewed.

A Documented Case Where Harm Came First

The limits of "no warning letter yet" aren't just theoretical. In 2015, a Florida clinic administered eye injections of patients' own fat-derived cells to three patients being treated for age-related macular degeneration. The treatment caused severe, in some cases permanent, vision loss in these patients. The FDA subsequently filed a federal lawsuit against the clinic, and in June 2019 a federal court ruled in the FDA's favor, confirming the agency's authority to regulate the clinic's stem cell procedures as unapproved drugs and ordering the clinic to stop performing them. The sequence matters: formal federal action came only after patients had already been seriously harmed, not before — illustrating exactly why "nothing has happened to this clinic yet" cannot be treated as evidence of safety.

What's Actually a More Meaningful Signal

Rather than relying on the absence of enforcement, there are more direct, checkable signals of legitimacy. Whether a specific cell product has received full FDA approval (a Biologics License Application, or BLA) for the condition being treated is the clearest marker — very few stem cell products hold this status today. Whether a treatment is offered only within a registered clinical trial, with an active FDA Investigational New Drug (IND) application and independent Institutional Review Board oversight, is another. And understanding the regulatory distinction between "361" human cell and tissue products — which can be minimally manipulated and marketed without pre-market FDA approval under narrower conditions — and "351" products, which are regulated as biologic drugs and require full approval before marketing, can help patients see through marketing language that conflates the two.

Bottom Line

A clean enforcement record is not the same thing as a clean bill of health. The FDA's warning-letter system flags problems after they're found, not before, and the sheer number of clinics marketing unapproved stem cell interventions — now numbering in the thousands — means most will never receive individual scrutiny at all. Patients are better served by checking a treatment's actual approval status, trial registration, and regulatory classification directly, rather than treating regulatory silence as a safety guarantee.